Incidence of Cytomegalovirus in Moderate Risk Kidney Transplant Recipients Receiving Low Dose Valganciclovir.

被引：0
|
作者：
Fallah, T. [1 ]
Logan, A. [2 ]
Garcia, L. Beltran [3 ]
Bowman, L. [2 ]
机构：
[1] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA
[2] Tampa Gen Hosp, Tampa, FL 33606 USA
[3] Tampa Gen Hosp, Florida Kidney Phys, Tampa, FL 33606 USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2019年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
A326
引用
下载
收藏
页码：722 / 722
页数：1
相关论文
共 50 条
  • [1] Incidence and Risk Factors for Leukopenia in Kidney Transplant Recipients Receiving Valganciclovir for Cytomegalovirus Prophylaxis
    Liang, Xinyun
    Famure, Olusegun
    Li, Yanhong
    Kim, S. Joseph
    PROGRESS IN TRANSPLANTATION, 2018, 28 (02) : 124 - 133
  • [2] Incidence of Cytomegalovirus and Role of Reduced Dose Valganciclovir in Kidney Transplant Recipients
    Szczepanik, A.
    Metzker, E.
    Burrelli, C.
    Chavin, K.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 810 - 811
  • [3] Incidence and Risk Factors for Leukopenia in Kidney Transplant Recipients Receiving Valganciclovir for Cytomegalovirus Prophylaxis.
    Liang, C.
    Famure, O.
    Li, Y.
    Kim, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 319 - 319
  • [4] Impact of Cytomegalovirus Infection in D+/R- Kidney Transplant Patients Receiving Six Months Low Dose Valganciclovir.
    Luan, F. L.
    Kommareddi, M.
    Park, J.
    Ojo, A. O.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 : 42 - 42
  • [5] Incidence of Cytomegalovirus Viremia and Pharmacoeconomic Analysis of Delayed-Initiation, Low-Dose Valganciclovir in Moderate Risk Kidney Transplant Patients
    Lourenco, L.
    West-Thielke, P.
    Hetterman, E.
    Thielke, J.
    TRANSPLANTATION, 2014, 98 : 812 - 812
  • [6] EFFICACY AND SAFETY OF LOW DOSE VERSUS HIGH DOSE VALGANCICLOVIR FOR PREVENTION OF CYTOMEGALOVIRUS DISEASE IN INTERMEDIATE RISK KIDNEY TRANSPLANT RECIPIENTS
    Halim, Medhat Abdel
    Al-Otaibi, Torki
    Gheith, Osama
    Adel, Hany
    Mosaad, Ahmed
    Abu-Atteya, Hassaneen
    Zakaria, Zakaria
    Makkeya, Yahia
    Said, Tarek
    Nair, Prasad
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 : 1568 - 1569
  • [7] COST BENEFIT OF CYTOMEGALOVIRUS DISEASE PREVENTION IN KIDNEY TRANSPLANT RECIPIENTS USING LOW DOSE VALGANCICLOVIR
    Gheith, Osama
    Halim, Medhat Abdul
    Al-Otaibi, Torki
    Adel, Hany
    Musaad, Ahemd
    Nair, Prasad
    TRANSPLANT INTERNATIONAL, 2017, 30 : 87 - 87
  • [8] Incidence of Cytomegalovirus Viremia and Pharmacoeconomic Analysis of Delayed-Initiation, Low-Dose Valganciclovir in Moderate Risk Kidney Transplant Patients.
    Lourenco, L.
    West-Thielke, P.
    Hetterman, E.
    Thielke, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 812 - 812
  • [9] Does Low-Dose Valganciclovir for Cytomegalovirus Prophylaxis Affect Outcomes in Kidney Transplant Recipients?
    Gillespie, M.
    Smith, L.
    Lee, S.
    Kenyon, N.
    Truax, C.
    Corbett, J.
    Shihab, F.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 322 - 322
  • [10] Low-Dose Valganciclovir for Cytomegalovirus Prophylaxis in Heart Transplant Recipients
    Julian, K. G.
    Shattahi, E.
    Burg, J. E.
    Boehmer, J. P.
    TRANSPLANTATION PROCEEDINGS, 2013, 45 (09) : 3414 - 3417
12345